Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Apparentely Multikine works best in HPV related cancers. Most of the H&N cancers are HPV related according to litterature.
Excellent analysis. I completely agree. Multikine will be even more effectieve when the immmune system and human body are in better shape to fight the HPV-related H&N cancer in stage3 vs stage4.
September 2019–>anticipated primary completion date. Much longer than expected. Results much better than expected and possibly realizing the same efficacy results (+33% vs SOC alone) as in phase2?
Who wants to buy shares from a company that needs a lot of capital until phase 3 results are announced?
Who wants to buy shares from a company from which you have to wait more than 1,5year before any substantial news will be announced?
I am not even sure they can maintain their $50m market cap.
Good news to wait so long, because results are better than expected? If that were the case the IDM board would have halted the trial already b/c of superior efficacy.
Bad news.
As I have said earlier.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147114384
Institutions are accumulating at this price level. They call it risk management.
When everybody is in, the train can leave.
Indeed
Ye$. We’re nearing money time!
More and more institutions buying shares of CVM. Another very good sign.
https://www.nasdaq.com/symbol/cvm/institutional-holdings
No Keytruda or Opdivo involved in the P3 trial, and still the trial is taking longer than expected (assuming 55% survival on SOC). Apparentely Multikine is working.
Page 20: https://cel-sci.com/wp-content/uploads/2019/02/CEL-SCI_Corporate_Presentation_website_022219.pdf
Always remember: companies cannot fake or fraud tumor shrinkage/elimination
With so many participants,statistical significance or insignificance will be seen by the IDMC in their next review. I don’t expect another update of the number of events anymore.
MAKE YOUR BET!
Fosco:Geert has the obligation to make an 8-k Filing from the moment he has the info the 298th event has occured. Other wise he’ll be sued.
Of course there will be an 8-K when the 298th event has happened, IMMEDIATELY after the CRO has informed the Company of it. That is material information which may not be withheld from investors!
Remember:companies cannot fake/fraud tumor shrinkage/elimination! I repeat the same sentence once every week.
It is an 8K event. Otherwise it is insider information.
About TEVA: “Investors are looking for something that will provide the company with a push forward.“
they’ll be buying out CVM for $2-6B (depending on how good the P3 results will be) , immediate revenues for Multikine (with lots of potential for other indications) and LT possibilities for LEAPS.
Took my +100% profits,now in CVM. P3 results out soon.
Sold at .95/share. I will get back in after dilution and a possoble reverse split
Jackpot! ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
“we believe Gencaro could potentially provide a new standard of treatment for AF prevention for the estimated 2.5 million HFmrEF patients in the major markets in U.S., Europe and Japan” P was 0.017! And 58% better results than the actieve comparator In P2!”
Should go to $2-4/share now with only 14million shares outstanding
https://finance.yahoo.com/news/arca-biopharma-announces-fda-agreement-123000757.html
Since Wall Street is closed on Monday,it could be Tuesday PM when we get the news.
Møre warrants will be converted now. Which is good. Ok share price could dip a little lower, but the higher the share price will go once positive results are out.
I agree. 5 million MC, if the P3 design is approved it’ll be very likely P3 will be succesfull. With potential annual revenues of upto $400m, market cap will explode.
FDA news before end of next week. If the FDA agrees with their single phase3 trial design, chances will be VERY high to be succesfull. That is because the subgroup of the phase2 trial reacted VERY positive to the treatment (p=0,017!!!!)
If its not going to be in 2019, than MK+SOC will bring more than 50% efficacy on overall survival over SOC alone and market value should be above $10,000,000,000 ($10B) or $200/share
I AGREE.
The consequences of a trial on overall survival -like this one- which lasts longer than expected are more extreme phase 3 results:
OR the beneficial effect of MK+SOC vs SOC is 5% or lower
OR the beneficial effect of MK+SOC vs SOC is 25-50%
Because we have well documented statistics on overall survival of stages 3 and 4a of H&N Cancer, I think we could be very surprised in a good way once the results are announced.
Remember: Companies cannot fake/fraud tumor shrinkage/elimination.
Multikine can be applied to all solid tumors.
Extra 12% going to 10% short in total. Number of OS=29million
==> Total short volume is 2,9 million
Previous short volume was 2,55 million
These are 335,000 shares extra that were short out of 29million. . .
My friend every stock in Wall Street has a number of shares that are shorted and sometimes it moves up and sometimes it moves down.
You are seeing ghosts!!! Just as you think I am multiple persons on other Message boards. If I read interesting things, I copy and I paste them, just as other people do.
I don’t call yelling that the stock has an increase in short percentage towards only 10% the same as providing excellent Information. In Europe we call that foolish.
Sushi,calm down man!10% short is very low!
https://www.investopedia.com/ask/answers/05/shortexceed50.asp
“When a company's short interest is high (above 40%) it means a large portion of the investors in the company are hoping the shares will go down in value.”
—> shorts don’t want to risk their house here. Risk/Reward for longs is much better for longs (down to $0, up to $100/share
—> stop making a fool of yourself!
Good news,max price raised from $2.74 to $2.84
When all warrants are converted (average price above $5) the fully diluted number of O/S is 44,000,000 shares
What’s your opinion of todays’ presentation? I am excited Geert removed the timeline. For me a sign that MK is working better than expected.
Personal PT: $100/share Meaning a conservative BO offer for $5b including manufacturing unit and LEAPS
Wow!!! This COULD become bigger than CART-cells!
I think institutions are follow you're calculations here guys. And if you are finally show to be right, they might offer you a $150,000/year salary job.
Thank you. Much clearer.
Amazing. But I don't understand anything about it
You are saying that the chances that the 10% target is met, is about 90-100% right now? Using the statistical method?
All statistical calculations are wrong, because it is a double blinded RANDOMISED trial:
—> stage 3 and 4a patients are not equally divided among SOC vs MK+SOC, and we all know stage 4a patients have less overall survival expectancy than stage 4a patients
—> the number of patients aren’t equally divided between all cancer centers. I am not telling news if I say that standard of care surgery in the U.S. is better than in India eg, and that the hygiene is better in the U.S. with less bacterial implications. I can give more examples of the benefit with living luxurious in the U.S. and Western Europe vs Africa/parts of Asia and Eastern Europe on the survival chances in cancer.
Your statistiscal spreadsheet can be used as a good guidance but nothing more, because it is RANDOMISED.
We are only sure of four things:
1. that Multikine has shown to reduce - and sometimes even eliminate - the tumor size
2. that Multikine has survived two interim data monitoring boards on efficacy and safety.
3. TEVA and Orient pharma have NEVER EVER quit their partnership on the Multikine trial
4. Not a single institution decided to sell shares since September 2018. Instead there was only increase in institutional ownership.
My Personal price target is $80/share (or $4B market cap)
Yes!! That’s excellent news!